US-based synthetic biology company Gen9 has raised $25m in funding from undisclosed investors to scale up its synthetic gene production, according to an SEC filing on Wednesday.
Gen9 recently launched a variant libraries product that allows users to test DNA variant combinations to examine their structure and function. The company is the creator of GeneByte Plus synthetic DNA, which can create DNA in lengths ranging from 3,000 to 10,000 base pairs.
The company raised $21m in April 2013 from electronic and bioanalytic measuring company Agilent Technologies. Gen9’s past investors also include Draper Fisher Jurvetson, Kraft Group and PBM Capital Group.